Compare ResMed Inc. (RMD) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs NEOS S&P 500 High Income ETF — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while NEOS S&P 500 High Income ETF trades at $53.97 (market cap $12.50B). The key difference: ResMed Inc. is far larger — about 2.6× NEOS S&P 500 High Income ETF's market cap, and ResMed Inc. pays a 1.16% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| RMD | SPYI | |
|---|---|---|
Market Cap | $31.89B | $12.50B |
Volume | 618,314 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $277.88 | $54.42 |
52-Week Low | $182.82 | $47.98 |
Typical Hold Time | 51 Days | 57 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
SPYI trades at $54.01, down 0.13% with a bullish technical outlook from moving averages but neutral oscillators. The ETF maintains consistent monthly dividend distributions around $0.53-$0.54, though recent analysis highlights concerns about principal erosion from covered call strategies. Media coverage focuses heavily on retirement income strategies and the trade-offs between high yields and capital preservation.
The outlook remains cautious as SPYI faces scrutiny over whether its high income distributions come at the expense of long-term capital growth. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of covered call returns and sequence risk for retirees present significant headwinds for investors seeking both income and principal protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
